We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Brainsway Ltd. Sponsored ADR (BWAY - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Brainsway Ltd. Sponsored ADR is a member of the Medical sector. This group includes 889 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Brainsway Ltd. Sponsored ADR is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for BWAY's full-year earnings has moved 12.2% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, BWAY has returned 77.1% so far this year. Meanwhile, stocks in the Medical group have lost about 7.5% on average. This means that Brainsway Ltd. Sponsored ADR is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is CG Oncology, Inc. (CGON - Free Report) . The stock is up 59.6% year-to-date.
Over the past three months, CG Oncology, Inc.'s consensus EPS estimate for the current year has increased 8.9%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Brainsway Ltd. Sponsored ADR belongs to the Medical - Products industry, a group that includes 78 individual stocks and currently sits at #168 in the Zacks Industry Rank. On average, stocks in this group have lost 22% this year, meaning that BWAY is performing better in terms of year-to-date returns.
CG Oncology, Inc., however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 433-stock industry is ranked #139. The industry has moved -2.4% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Brainsway Ltd. Sponsored ADR and CG Oncology, Inc. as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Brainsway Ltd. Sponsored ADR (BWAY - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Brainsway Ltd. Sponsored ADR is a member of the Medical sector. This group includes 889 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Brainsway Ltd. Sponsored ADR is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for BWAY's full-year earnings has moved 12.2% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, BWAY has returned 77.1% so far this year. Meanwhile, stocks in the Medical group have lost about 7.5% on average. This means that Brainsway Ltd. Sponsored ADR is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is CG Oncology, Inc. (CGON - Free Report) . The stock is up 59.6% year-to-date.
Over the past three months, CG Oncology, Inc.'s consensus EPS estimate for the current year has increased 8.9%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Brainsway Ltd. Sponsored ADR belongs to the Medical - Products industry, a group that includes 78 individual stocks and currently sits at #168 in the Zacks Industry Rank. On average, stocks in this group have lost 22% this year, meaning that BWAY is performing better in terms of year-to-date returns.
CG Oncology, Inc., however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 433-stock industry is ranked #139. The industry has moved -2.4% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Brainsway Ltd. Sponsored ADR and CG Oncology, Inc. as they attempt to continue their solid performance.